ArticleJournal of cancer research and clinical oncology2014
Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
Article in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Sirolimus for vascular anomalies in the first year of life: a systematic review.Journal of perinatology : official journal of the California Perinatal Association · 2024Pooled it
- Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience.Scientific reports · 2016Trial
- Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.Pediatrics · 2016Trial
- Kaposiform lymphangiomatosis-the effects of long-term treatment with sirolimus: case series study and review of the literature.Frontiers in medicine · 2026Article
- Treatment of Kasabach-Merritt syndrome in infants' maxillofacial regions with local, accurate administration of urea combined with methylprednisolone.Oral and maxillofacial surgery · 2025Article
- Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.British journal of clinical pharmacology · 2022Article
- ISSVA Classification of Vascular Anomalies and Molecular Biology.International journal of molecular sciences · 2022Review
- Case report: Kaposi hemangioendothelioma of the right upper limb with the Kasabach-Merritt phenomenon: A potentially lethal diagnostic challenge.Frontiers in pediatrics · 2022Article
- Multidisciplinary management of a neonate with kaposiform hemangioendothelioma with extensive cranial fossa destruction.SAGE open medical case reports · 2022Article
- Initial dose recommendation for sirolimus in paediatric kaposiform haemangioendothelioma patients based on population pharmacokinetics and pharmacogenomics.The Journal of international medical research · 2020Article
- Kaposiform hemangioendothelioma: current knowledge and future perspectives.Orphanet journal of rare diseases · 2020Review
- Successful treatment of a patient with Kasabach-Merritt syndrome and multiple giant hepatic hemangiomas.The Journal of international medical research · 2020Article
- Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study.Oncology letters · 2019Article
- Kaposiform hemangioendothelioma without cutaneous involvement.Journal of cancer research and clinical oncology · 2018Article
- Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options.World journal of pediatrics : WJP · 2018Review
- Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus.The Journal of dermatology · 2018Article
- Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: a Case Report and Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2018Article
- Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis.Rare tumors · 2018Article
- Intestinal obstruction due to kaposiform hemangioendothelioma in a 1-month-old infant: A case report.Medicine · 2017Article
- Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon.JAAD case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that usually occurs in infants. It is commonly associated with Kasabach-Merritt phenomenon which is directly responsible for the significant morbidity and mortality, including hemodynamic instability, local invasion, and compression of vital structures. Treatment is particularly difficult for those who had no response to conventional therapies. This paper wants to share experience of mTOR inhibitors sirolimus in the treatment of refractory KHE. MATERIALS AND
methodsSix cases of refractory KHE were diagnosed and treated in Children's Hospital of Fudan University from Jan 2010-June 2013; all of them were treated with sirolimus in June 2012 after failing multiple other therapies.
resultsIn six patients, gender was equally distributed between male and female patients. The mean age at the time of initial diagnosed as KHE was 3.1 ± 1.8 months. All of them had been pretreated with at least 2 medical therapies. All of them showed significant improvement in clinical status with tolerable side effects. The average time to response was 5.3 ± 1.0 days; the average stabilization time of platelet was 15.1 ± 8.0 days; and the average time for sirolimus treated as single agent was 1.7 ± 0.4 months. No recurrence of their symptoms happened.
conclusionsSirolimus appears to be effective and safe in patients with life-threatening KHE and represents a promising tool in treating refractory KHE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.